Skip to content
Home
Robert C. Rose, Ph.D.

Robert C. Rose, Ph.D.

Contact

Office (585) 275-0263
Administrative (585) 275-5871

Looking for more Information?

Visit my lab website to learn more about my research, collaborators, latest news, etc.

Visit Research Lab Website

About Me

Faculty Appointments

Professor Emeritus - Department of Medicine, Infectious Diseases (SMD)

Credentials

Education

PhD | Univ Rochester Sch Med/Dent. Virology. 1994

MS | Univ Rochester Sch Med/Dent. Microbiology. 1990

BS | SUNY Geneseo. Biology. 1984

Awards

George Eastman Medal for Outstanding Achievement. 2009

Health Care Achievement Award. 2007

Inspiration Award. 2007

Distinguished Inventor of the Year Award. 2006

United States Congressional Record. 2006

Davey Memorial Award for Outstanding Cancer Research. 2005

Melville A. Hare Distinguished Research Award. 1994

Research

Genital infection with any of several human papillomaviruses (HPVs) is necessary but not sufficient to cause uterine cervical cancer, the second most common female malignancy worldwide. In the late 1980s we established antibody-mediated virus neutralization as a vaccine concept for prevention of gen...
Genital infection with any of several human papillomaviruses (HPVs) is necessary but not sufficient to cause uterine cervical cancer, the second most common female malignancy worldwide. In the late 1980s we established antibody-mediated virus neutralization as a vaccine concept for prevention of genital HPV infections by using authentic virions of a genital HPV type (type 11 or "HPV11") to demonstrate that viral infectivity could be blocked with capsid-specific antibodies. This observation led us to produce non-infectious "virus-like particles" (VLPs) of prevalent genital HPV types associated with either benign genital warts (HPV11) (1) or cervical cancer (HPV16 and HPV18) (3). By comparing HPV11 recombinant VLPs with authentic native genital HPV11 virions, we were able to show that VLPs accurately mimic viral structure and immunological properties. We then formally demonstrated that this approach to vaccine development was valid by showing that antibodies raised against HPV11 L1 VLPs efficiently neutralized authentic HPV11 virus particles (2).Our subsequent evaluations of antibody responses against VLPs derived from three genetically distinct genital HPV types (i.e., types 11, 16 and 18) led us to conclude that antibody-mediated neutralization was genotype-specific, and that multivalent HPV VLP vaccine formulations would be required for the induction of broadly protective immunity against genital HPV disease (3)(4).

We next developed a collaboration with a small biotechnology company (MedImmune, Inc., Gaithersburg, MD), and performed the first-in-humans administration of VLPs in a controlled phase 1 clinical study of VLP safety and tolerability. The results of our study indicated that VLPs are safe and well-tolerated (11). Next, phase 2 and phase 3 clinical studies were performed by GlaxoSmithKline, and by Merck, Sharp & Dohme. Results from those studies demonstrated that VLP vaccines are highly effective for preventing cervical cancer precursor lesions. In June 2006, Gardasil (a tetravalent VLP vaccine formulation made by Merck) was approved by the FDA, and recommended by the CDC's Advisory Committee on Immunization Practices (ACIP) for universal immunization of 11 and 12 year old females. A bivalent formulation developed by Glaxosmithkline is now under FDA review.

More recently our work has involved the development of alternative needle-free methods for VLP administration that we hope will prove to be more suitable for use in developing world regions where most cervical cancer occurs (8, 9, 13). We are also developing chimeric VLP-based vaccines for therapy of established genital HPV disease, or for preventing or treating diseases caused by other viruses including HIV and Dengue.

Patents

Oral Immunization with Papillomavirus Virus-Like Particles

Issue date: November 28, 2000

Homogeneous Human Papillomavirus Capsomere Containing Compositions, Methods for Manufacture, and Use Thereof as Diagnostic, Prophylactic or Therapeutics Agents

Issue date: December 26, 2000

Production of Human Papillomavirus Virus Capsid Protein and Virus-Like Particles

Issue date: October 11, 2007

Production of Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: November 22, 2011

Papillomavirus Capsid Protein and Virus-like Particles

Issue date: October 11, 2011

Production of Papillomavirus Capsid Protein and Virus-like Particles

Issue date: May 25, 2005

Transcutaneous Immunization Against Papillomavirus Disease

Issue date: June 23, 2010

Transcutaneous Immunization Against Papillomavirus with Papillomavirus Virus-like Particles

Issue date: July 24, 2007

Transcutaneous Immunization Against Papillomavirus with Papillomavirus Virus-Like Particles

Issue date: October 16, 2012

Transcutaneous Immunization Against Papillomavirus with Papillomavirus Virus-Like Particles

Issue date: October 02, 2008

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: January 05, 2011

Production of Human Papillomavirus HBV-11 Capsid Protein L1 and Virus-Like Particles

Issue date: December 22, 2010

Homogeneous Human Papillomavirus Capsomere Containing Compositions, Methods for Manufacture, and Use Thereof as Diagnostic, Prophylactic, or Therapeutic Agents

Issue date: January 25, 1999

Homogeneous Human Papillomavirus Capsomere Containing Compositions, Methods for Manufacture, and Use Thereof as Diagnostic, Prophylactic, or Therapeutic Agents

Issue date: June 26, 2007

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: May 01, 2011

Production of Human Papillomavirus HBV-11 Capsid Protein L1 and Virus-Like Particles

Issue date: August 05, 2011

Production of Human Papillomavirus Capsid Protein and Virus-like Particles

Issue date: April 02, 2010

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: November 25, 2010

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: November 28, 2010

Method of Determining Immune Enhancement of Virus Infectivity using FC Receptor-Transfected Cell Lines

Issue date: November 26, 2013

Method of Determining Immune Enhancement of Virus Infectivity Using Fc Receptor-Transfected Cell Lines

Issue date: January 05, 2012

Rapid Diagnostic Chips for Detection of Immune Responses to HPV (Human Papilloma Virus)

Issue date: May 28, 2013

Combined Human Papillomavirus VLP/Gene Delivery System and Use Thereof As a Vaccine for Prophylaxis and Immunotherapy of Infectious Diseases and Tumors

Issue date: July 15, 2014

Production of Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: October 11, 2013

Production of Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: July 05, 2013

Transcutaneous Immunization Against Papillomavirus Disease

Issue date: June 23, 2010

Transcutaneous Immunization Against Papillomavirus Disease

Issue date: June 23, 2010

Transcutaneous Immunization Against Papillomavirus Disease

Issue date: June 23, 2010

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: January 05, 2011

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: January 05, 2011

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: January 05, 2011

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: January 05, 2011

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: January 05, 2011

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: January 05, 2011

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: January 05, 2011

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: January 05, 2011

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: January 05, 2011

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: January 05, 2011

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: January 05, 2011

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: January 05, 2011

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: January 05, 2011

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: January 05, 2011

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: January 05, 2011

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: January 05, 2011

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: December 22, 2010

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: December 22, 2010

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: December 22, 2010

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: December 22, 2010

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: December 22, 2010

Production of Human Papillomavirus Capsid Protein and Virus-Like Particles

Issue date: December 22, 2010

Arrayed Detector System for Measurement of Anti-Viral Immune Response

Issue date: May 19, 2015

Publications

Journal Articles

Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype.

Rodrigo WW, Block OK, Lane C, Sukupolvi-Petty S, Goncalvez AP, Johnson S, Diamond MS, Lai CJ, Rose RC, Jin X, Schlesinger JJ

Virology.. 2009 November 25394 (2):175-82. Epub 10/14/2009.

Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres.

Murata Y, Lightfoote PM, Rose RC, Walsh EE

Virology journal.. 2009 June 186 :81. Epub 06/18/2009.

Difference between the abilities of human Fcgamma receptor-expressing CV-1 cells to neutralize American and Asian genotypes of dengue virus 2.

Rodrigo WW, Alcena DC, Kou Z, Kochel TJ, Porter KR, Comach G, Rose RC, Jin X, Schlesinger JJ

Clinical and vaccine immunology : CVI.. 2009 February 16 (2):285-7. Epub 11/26/2008.

An automated Dengue virus microneutralization plaque assay performed in human Fc{gamma} receptor-expressing CV-1 cells.

Shanaka WW, Rodrigo I, Alcena DC, Rose RC, Jin X, Schlesinger JJ

The American journal of tropical medicine and hygiene.. 2009 January 80 (1):61-5. Epub 1900 01 01.

Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells.

Kou Z, Quinn M, Chen H, Rodrigo WW, Rose RC, Schlesinger JJ, Jin X

Journal of medical virology.. 2008 January 80 (1):134-46. Epub 1900 01 01.

Primary human splenic macrophages, but not T or B cells, are the principal target cells for dengue virus infection in vitro.

Blackley S, Kou Z, Chen H, Quinn M, Rose RC, Schlesinger JJ, Coppage M, Jin X

Journal of virology.. 2007 December 81 (24):13325-34. Epub 10/10/2007.

Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo.

Malboeuf CM, Simon DA, Lee YE, Lankes HA, Dewhurst S, Frelinger JG, Rose RC

Vaccine.. 2007 April 3025 (17):3270-6. Epub 01/22/2007.

Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles.

Ryan EP, Malboeuf CM, Bernard M, Rose RC, Phipps RP

The Journal of immunology : official journal of the American Association of Immunologists.. 2006 December 1177 (11):7811-9. Epub 1900 01 01.

Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32).

Rodrigo WW, Jin X, Blackley SD, Rose RC, Schlesinger JJ

Journal of virology.. 2006 October 80 (20):10128-38. Epub 1900 01 01.

Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York.

Luque AE, Jabeen M, Messing S, Lane CA, Demeter LM, Rose RC, Reichman RC

The Journal of infectious diseases.. 2006 August 15194 (4):428-34. Epub 07/13/2006.

Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.

Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM

The Journal of immunology : official journal of the American Association of Immunologists.. 2005 June 15174 (12):7516-23. Epub 1900 01 01.

Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids.

Sasagawa T, Rose RC, Azar KK, Sakai A, Inoue M

International journal of cancer.. 2003 April 10104 (3):328-35. Epub 1900 01 01.

A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers.

Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA, O'Brien D, Campbell M, White WI, Balsley J, Reichman RC

The Journal of infectious diseases.. 2001 May 15183 (10):1485-93. Epub 04/24/2001.

Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.

Gerber S, Lane C, Brown DM, Lord E, DiLorenzo M, Clements JD, Rybicki E, Williamson AL, Rose RC

Journal of virology.. 2001 May 75 (10):4752-60. Epub 1900 01 01.

Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies.

Rose RC, Lane C, Wilson S, Suzich JA, Rybicki E, Williamson AL

Vaccine.. 1999 April 2317 (17):2129-35. Epub 1900 01 01.

Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.

Rose RC, White WI, Li M, Suzich JA, Lane C, Garcea RL

Journal of virology.. 1998 July 72 (7):6151-4. Epub 1900 01 01.

Isolation and propagation of human papillomavirus type 16 in human xenografts implanted in the severe combined immunodeficiency mouse.

Bonnez W, DaRin C, Borkhuis C, de Mesy Jensen K, Reichman RC, Rose RC

Journal of virology.. 1998 June 72 (6):5256-61. Epub 1900 01 01.

Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles.

Rose RC, Bonnez W, Da Rin C, McCance DJ, Reichman RC

The Journal of general virology.. 1994 September 75 ( Pt 9) :2445-9. Epub 1900 01 01.

Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera.

Rose RC, Reichman RC, Bonnez W

The Journal of general virology.. 1994 August 75 ( Pt 8) :2075-9. Epub 1900 01 01.

Evaluation of temperature sensitivity of human papillomavirus type 11 by using the human xenograft severe combined immunodeficiency mouse model.

Bonnez W, Rose RC, Borkhuis C, Da Rin C, Reichman RC

Journal of clinical microbiology.. 1994 June 32 (6):1575-7. Epub 1900 01 01.

Two E2 binding sites (E2BS) alone or one E2BS plus an A/T-rich region are minimal requirements for the replication of the human papillomavirus type 11 origin.

Lu JZ, Sun YN, Rose RC, Bonnez W, McCance DJ

Journal of virology.. 1993 December 67 (12):7131-9. Epub 1900 01 01.

Propagation of human papillomavirus type 11 in human xenografts using the severe combined immunodeficiency (SCID) mouse and comparison to the nude mouse model.

Bonnez W, Rose RC, Da Rin C, Borkhuis C, de Mesy Jensen KL, Reichman RC

Virology.. 1993 November 197 (1):455-8. Epub 1900 01 01.

Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles.

Rose RC, Bonnez W, Reichman RC, Garcea RL

Journal of virology.. 1993 April 67 (4):1936-44. Epub 1900 01 01.

Evolution of the antibody response to human papillomavirus type 11 (HPV-11) in patients with condyloma acuminatum according to treatment response.

Bonnez W, Da Rin C, Rose RC, Tyring SK, Reichman RC

Journal of medical virology.. 1993 April 39 (4):340-4. Epub 1900 01 01.

Antibody response to human papillomavirus (HPV) type 11 in children with juvenile-onset recurrent respiratory papillomatosis (RRP).

Bonnez W, Kashima HK, Leventhal B, Mounts P, Rose RC, Reichman RC, Shah KV

Virology.. 1992 May 188 (1):384-7. Epub 1900 01 01.

Antibody-mediated neutralization of human papillomavirus type 11 (HPV-11) infection in the nude mouse: detection of HPV-11 mRNAs.

Bonnez W, Rose RC, Reichman RC

The Journal of infectious diseases.. 1992 February 165 (2):376-80. Epub 1900 01 01.

Use of human papillomavirus type 11 virions in an ELISA to detect specific antibodies in humans with condylomata acuminata.

Bonnez W, Da Rin C, Rose RC, Reichman RC

The Journal of general virology.. 1991 June 72 ( Pt 6) :1343-7. Epub 1900 01 01.

Expression of the full-length products of the human papillomavirus type 6b (HPV-6b) and HPV-11 L2 open reading frames by recombinant baculovirus, and antigenic comparisons with HPV-11 whole virus particles.

Rose RC, Bonnez W, Strike DG, Reichman RC

The Journal of general virology.. 1990 November 71 ( Pt 11) :2725-9. Epub 1900 01 01.

Expression in Escherichia coli of seven DNA fragments comprising the complete L1 and L2 open reading frames of human papillomavirus type 6b and localization of the 'common antigen' region.

Strike DG, Bonnez W, Rose RC, Reichman RC

The Journal of general virology.. 1989 March 70 ( Pt 3) :543-55. Epub 1900 01 01.

Books

Perspectives in Medical Virology (2002)

Chapter: Human Papillomavirus Immunology and Vaccine Development

Antiviral Agents and Human Viral Diseases (1997)

Chapter: Human Papillomavirus Infections